Business Wire

Adtran brings its latest coherent innovation to OFCnet multi-vendor demo

7.3.2023 16:00:00 EET | Business Wire | Press release

Share

Adtran®, Inc., (NASDAQ:ADTN), the leading provider of open and disaggregated networking solutions, today announced that its latest coherent innovation will be showcased at OFC as part of OFCnet. The demo reveals how the Adtran FSP 3000 open line system (OLS) can bring new levels of flexibility to optical networks by enabling optimized, tailored spectrum services. In collaboration with Acacia, Cisco, Coherent Corp., Corning, EXFO, Nokia and VIAVI Solutions, Adtran will showcase 100ZR, 200Gbit/s, 400Gbit/s OpenZR+ and 800Gbit/s connectivity. The FSP 3000 DCI OLS is also playing a key role in the OIF 400ZR demo at OFC.

“Our demo shows how the spectrum-as-a-service concept has the potential to revolutionize the way operators utilize their fiber resources. It highlights how it’s possible to slice up the network even in a metro environment. With fully flexible spectrum allocation, operators can provide a wide variety of differentiated services and ensure they leverage the full capacity of their infrastructure. Not only will this help tackle ever-increasing data demand, but it also offers a new route to revenue growth,” said Jörg-Peter Elbers, head of advanced technology at Adtran. “Our compact FSP 3000 OLS is the key to realizing the full benefits of this open and flexible approach. It removes the limits of fixed channel grids so that untapped spectrum can be put to work.”

The coherent innovation demo features a three-node ring network with flexgrid ROADMs in the Adtran, Coherent Corp. and OFCnet booths. Adtran’s FSP 3000 OLS is used to ensure strict separation between users while minimizing the unused bandwidth between their spectrum services, and its high-resolution flexgrid ROADMs provide optical channel monitoring, demarcation and passband optimization for all spectrum services. Also on display is the Adtran TeraFlex™ CoreChannel™, which transports 100Gbit/s and 400Gbit/s Ethernet client signals over a coherent 800Gbit/s signal. In combination with Adtran’s MicroMux™, the terminal shows the transmission of 10Gbit/s services without any footprint increase. What’s more, Adtran’s OpenFabric+™ is being used to demonstrate 200Gbit/s connectivity.

“One of the most exciting elements of this demo is showcasing the value of our Coherent 100ZR. To meet growing traffic demands, network operators need to upgrade their edge aggregation infrastructure to support 100Gbit/s rates. However, this can be a costly and complex process. With its QSFP28 form factor, our Coherent 100ZR easily fits into existing host platforms and can operate over any optical network infrastructure. This facilitates the adoption of 100Gbit/s coherent technology at the network edge without major infrastructure changes and at an affordable price,” commented Ross Saunders, GM of Optical Engines, Adtran. “With a new purpose-built DSP, a standards-compliant QSFP28 form factor, and 5W power consumption, our Coherent 100ZR opens the door to widespread rollout of 100Gbit/s coherent technology at the optical edge.”

About Adtran
Adtran, Inc. is a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. Adtran, Inc. is a wholly-owned subsidiary of ADTRAN Holdings, Inc. (NASDAQ:ADTN and FSE: QH9). Find more at Adtran, LinkedIn and Twitter.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Published by
Adtran, Inc.
www.adtran.com

For media
Gareth Spence
t +44 1904 699 358
public-relations@adva.com

For investors
Rhonda Lambert
t +1 256-963-7450
investor@adtran.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye